BR112022008752A2 - Métodos e sistemas para a análise de moléculas de ácido nucleico - Google Patents

Métodos e sistemas para a análise de moléculas de ácido nucleico

Info

Publication number
BR112022008752A2
BR112022008752A2 BR112022008752A BR112022008752A BR112022008752A2 BR 112022008752 A2 BR112022008752 A2 BR 112022008752A2 BR 112022008752 A BR112022008752 A BR 112022008752A BR 112022008752 A BR112022008752 A BR 112022008752A BR 112022008752 A2 BR112022008752 A2 BR 112022008752A2
Authority
BR
Brazil
Prior art keywords
analysis
systems
methods
nucleic acid
acid molecules
Prior art date
Application number
BR112022008752A
Other languages
English (en)
Portuguese (pt)
Inventor
M Kurtz David
Diehn Maximilian
Ash Alizadeh Arash
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BR112022008752A2 publication Critical patent/BR112022008752A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20—Screening of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Databases & Information Systems (AREA)
  • Library & Information Science (AREA)
  • Bioethics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
BR112022008752A 2019-11-06 2020-11-06 Métodos e sistemas para a análise de moléculas de ácido nucleico BR112022008752A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931688P 2019-11-06 2019-11-06
PCT/US2020/059526 WO2021092476A1 (en) 2019-11-06 2020-11-06 Methods and systems for analyzing nucleic acid molecules

Publications (1)

Publication Number Publication Date
BR112022008752A2 true BR112022008752A2 (pt) 2022-08-16

Family

ID=75848071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008752A BR112022008752A2 (pt) 2019-11-06 2020-11-06 Métodos e sistemas para a análise de moléculas de ácido nucleico

Country Status (14)

Country Link
US (14) US20210172022A1 (https=)
EP (3) EP4527945A3 (https=)
JP (2) JP7825272B2 (https=)
KR (1) KR20220094218A (https=)
CN (3) CN118374597A (https=)
AU (1) AU2020378435A1 (https=)
BR (1) BR112022008752A2 (https=)
CA (1) CA3156589A1 (https=)
DE (1) DE112020005433T5 (https=)
DK (1) DK4055187T3 (https=)
ES (1) ES3041276T3 (https=)
GB (4) GB2613427B (https=)
MX (1) MX2022005588A (https=)
WO (1) WO2021092476A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613787B2 (en) 2019-11-06 2023-03-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970916C (en) 2014-03-14 2025-02-04 Caredx, Inc. METHODS FOR MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT
KR20230064172A (ko) * 2021-11-03 2023-05-10 주식회사 지씨지놈 세포유리 핵산단편 위치별 서열 빈도 및 크기를 이용한 암 진단 방법
MX2024006820A (es) * 2021-12-15 2024-08-15 Univ Johns Hopkins Mutacion del genoma completo de molecula unica y perfiles de fragmentacion de acido desoxirribonucleico (adn) libre de celula.
CN114974421B (zh) * 2022-05-20 2024-04-30 南开大学 基于扩散-降噪的单细胞转录组测序数据补插方法及系统
KR20230172174A (ko) * 2022-06-15 2023-12-22 주식회사 지씨지놈 무세포 핵산의 단일염기변이를 이용한 암 진단 및 암 종 예측방법
CN115181800B (zh) * 2022-07-11 2025-06-13 南京世和基因生物技术股份有限公司 基因标志物在非小细胞肺癌预后效果预测中的应用、预测装置以及计算机可读取介质
GB202212094D0 (en) * 2022-08-19 2022-10-05 Inivata Ltd Method of detecting cancer DNA in a sample
CN116466085A (zh) * 2022-11-28 2023-07-21 中国人民解放军海军军医大学第三附属医院 一种四基因的生物标志物组合及其在肝癌治疗中的应用
KR102630597B1 (ko) * 2023-08-22 2024-01-29 주식회사 지놈인사이트테크놀로지 종양 정보를 활용한 미세 잔존 질환 탐지 방법 및 장치
US20250140343A1 (en) * 2023-10-30 2025-05-01 Myriad Women's Health, Inc. Methods for improving minimal residual disease assays
WO2025245136A1 (en) * 2024-05-22 2025-11-27 Foresight Diagnostics Inc. Methods and systems for adjuvant therapy
WO2026019737A1 (en) * 2024-07-16 2026-01-22 Myriad Women's Health, Inc. Targeted depletion sequencing for use in minimum residual disease assays
WO2026072949A1 (en) * 2024-09-27 2026-04-02 Roche Sequencing Solutions, Inc. Multi-modal risk stratification of minimum residual disease

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA241076A (en) 1924-06-24 Carter Formby King Otis Calculating apparatus
CA233975A (en) 1923-09-04 Rightmire Franklin Anti-skid chain tightener
CA188298A (en) 1918-04-08 1919-01-14 William H. Bot Grain separator
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6171856B1 (en) 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
DE10032165A1 (de) 2000-07-01 2002-01-10 Beiersdorf Ag Verwendung von physiologisch verträglichen Sulfinsäuren als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen
NZ532780A (en) 2001-12-21 2006-10-27 Wellcome Trust Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them
CN101501211A (zh) 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
WO2011103236A2 (en) 2010-02-18 2011-08-25 The Johns Hopkins University Personalized tumor biomarkers
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
CA2811185C (en) 2010-09-21 2020-09-22 Population Genetics Technologies Ltd. Increasing confidence of allele calls with molecular counting
KR20190002733A (ko) 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
ES2625288T3 (es) 2011-04-15 2017-07-19 The Johns Hopkins University Sistema de secuenciación segura
DK2814959T3 (en) 2012-02-17 2018-04-23 Hutchinson Fred Cancer Res COMPOSITIONS AND PROCEDURES FOR EXACTLY IDENTIFYING MUTATIONS
EP3744857A1 (en) 2012-03-20 2020-12-02 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
GB2533006B (en) 2012-09-04 2017-06-07 Guardant Health Inc Systems and methods to detect copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
EP3885446A1 (en) 2013-02-01 2021-09-29 The Regents of The University of California Methods for genome assembly and haplotype phasing
CN113337604A (zh) 2013-03-15 2021-09-03 莱兰斯坦福初级大学评议会 循环核酸肿瘤标志物的鉴别和用途
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
EP3957749A1 (en) 2014-04-21 2022-02-23 Natera, Inc. Detecting tumour specific mutations in biopsies with whole exome sequencing and in cell-free samples
WO2015169947A1 (en) * 2014-05-09 2015-11-12 Lifecodexx Ag Detection of dna that originates from a specific cell-type and related methods
AU2015269103B2 (en) * 2014-06-06 2021-12-23 Cornell University Method for identification and enumeration of nucleic acid sequence, expression, copy, or DNA methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions
MX2016016904A (es) * 2014-06-26 2017-03-27 10X Genomics Inc Analisis de secuencias de acidos nucleicos.
EP3191628B1 (en) 2014-09-12 2022-05-25 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acids
WO2016049878A1 (zh) * 2014-09-30 2016-04-07 深圳华大基因科技有限公司 一种基于snp分型的亲子鉴定方法及应用
CN107002131B (zh) 2014-11-12 2022-04-29 尼欧基因组学实验室股份有限公司 作为确认骨髓增生异常综合征诊断的可靠测试的外周血血浆dna深度测序
WO2016130578A1 (en) 2015-02-09 2016-08-18 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
ES2969767T3 (es) 2015-05-01 2024-05-22 Guardant Health Inc Métodos de diagnóstico
CA3002740A1 (en) 2015-10-19 2017-04-27 Dovetail Genomics, Llc Methods for genome assembly, haplotype phasing, and target independent nucleic acid detection
WO2017075436A1 (en) 2015-10-30 2017-05-04 New England Biolabs, Inc. Compositions and methods for determining modified cytosines by sequencing
US10260088B2 (en) 2015-10-30 2019-04-16 New England Biolabs, Inc. Compositions and methods for analyzing modified nucleotides
EP3384050A4 (en) 2015-12-03 2019-07-31 Alfred Health MONITORING THE TREATMENT OR PROGRESSION OF MYELOMA
PL3387152T3 (pl) 2015-12-08 2022-05-09 Twinstrand Biosciences, Inc. Ulepszone adaptory, sposoby i kompozycje do sekwencjonowania dupleksowego
CN109072309B (zh) 2016-02-02 2023-05-16 夸登特健康公司 癌症进化检测和诊断
US11479878B2 (en) * 2016-03-16 2022-10-25 Dana-Farber Cancer Institute, Inc. Methods for genome characterization
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
GB2600627B (en) 2016-05-27 2022-12-07 Personalis Inc Personalized genetic testing
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
WO2018081161A1 (en) 2016-10-24 2018-05-03 Biomatrica, Inc. Stabilization of nucleic acids on paper
EP4134444B1 (en) 2017-03-23 2024-10-02 University of Washington Methods for targeted nucleic acid sequence enrichment with applications to error corrected nucleic acid sequencing
US11342047B2 (en) * 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
US11542540B2 (en) 2017-06-16 2023-01-03 Life Technologies Corporation Control nucleic acids, and compositions, kits, and uses thereof
EP3654763A4 (en) 2017-06-28 2021-06-09 Dow Agrosciences LLC PLANT PROMOTER FOR TRANSGENIC EXPRESSION
EP3685386A1 (en) 2017-09-20 2020-07-29 Guardant Health, Inc. Methods and systems for differentiating somatic and germline variants
EP3762512A1 (en) 2018-03-06 2021-01-13 Cancer Research Technology Limited Improvements in variant detection
CN109337983A (zh) * 2018-11-29 2019-02-15 优葆优保健康科技(宁波)有限公司 检测人甲状腺癌循环肿瘤dna的探针组合及其捕获测序系统
EP3914736B1 (en) * 2019-01-25 2023-12-20 Grail, LLC Detecting cancer, cancer tissue of origin, and/or a cancer cell type
KR102526916B1 (ko) * 2019-04-05 2023-05-02 주식회사 제놉시 Cfdna를 이용한 위암 진단방법
CN110055312B (zh) * 2019-04-09 2022-11-15 嘉兴雅康博医学检验所有限公司 用于检测egfr基因c797s和t790m顺反式突变的引物、探针及试剂盒
WO2021003485A1 (en) 2019-07-03 2021-01-07 The Board Of Trustees Of The Leland Stanford Junior University Methods to assess clinical outcome based upon updated probabilities and treatments thereof
WO2021092476A1 (en) 2019-11-06 2021-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
AU2021225854A1 (en) 2020-02-24 2022-10-13 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for protecting nucleic-acid molecules
JP2024519501A (ja) 2021-05-05 2024-05-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 核酸分子を分析するための方法およびシステム
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613787B2 (en) 2019-11-06 2023-03-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11851716B2 (en) 2019-11-06 2023-12-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11965215B2 (en) 2019-11-06 2024-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules

Also Published As

Publication number Publication date
GB202404419D0 (en) 2024-05-08
JP7825272B2 (ja) 2026-03-06
CN118834950A (zh) 2024-10-25
US20230124070A1 (en) 2023-04-20
EP4527945A2 (en) 2025-03-26
JP2024028940A (ja) 2024-03-05
GB2627085B (en) 2024-11-13
CA3156589A1 (en) 2021-05-14
ES3041276T3 (en) 2025-11-11
GB2613427B (en) 2024-01-17
DE112020005433T5 (de) 2022-10-06
AU2020378435A1 (en) 2022-05-26
US12492434B2 (en) 2025-12-09
MX2022005588A (es) 2022-08-16
GB2623904B (en) 2024-07-24
US11965215B2 (en) 2024-04-23
GB2623904A (en) 2024-05-01
US20220139497A1 (en) 2022-05-05
CN118374597A (zh) 2024-07-23
GB202212061D0 (en) 2022-10-05
US20220208303A1 (en) 2022-06-30
KR20220094218A (ko) 2022-07-05
US20210172022A1 (en) 2021-06-10
US11613787B2 (en) 2023-03-28
US20240026460A1 (en) 2024-01-25
GB2613427A (en) 2023-06-07
US11851716B2 (en) 2023-12-26
US20220340980A1 (en) 2022-10-27
US11634779B2 (en) 2023-04-25
US20230203597A1 (en) 2023-06-29
DK4055187T3 (da) 2025-10-27
US20230250485A1 (en) 2023-08-10
US20240035095A1 (en) 2024-02-01
EP4055187A4 (en) 2023-11-01
JP2023501376A (ja) 2023-01-18
EP4055187B1 (en) 2025-08-20
GB2595193B (en) 2022-10-12
EP4055187A1 (en) 2022-09-14
US20210366571A1 (en) 2021-11-25
EP4527945A3 (en) 2025-06-18
EP4365309A3 (en) 2024-08-21
GB2595193A (en) 2021-11-17
GB2627085A (en) 2024-08-14
US11447833B2 (en) 2022-09-20
WO2021092476A1 (en) 2021-05-14
US20220251664A1 (en) 2022-08-11
GB202112217D0 (en) 2021-10-13
US20240175088A1 (en) 2024-05-30
CN113383085A (zh) 2021-09-10
JP7807089B2 (ja) 2026-01-27
US20220389518A1 (en) 2022-12-08
GB202318607D0 (en) 2024-01-17
US20230183816A1 (en) 2023-06-15
EP4365309A2 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
BR112022008752A2 (pt) Métodos e sistemas para a análise de moléculas de ácido nucleico
PH12020500103A1 (en) Use of cas protein, method for detecting target nucleic acid molecule, and kit
BR112015013234A2 (pt) métodos de detecção de ácido nucleico multiplex
MY195999A (en) Molecular Detection/Diagnosis Reagent for Tumor
BR112018015913A2 (pt) método para determinar uma variação no número de cópia de uma sequência de ácido nucleico de interesse, e, sistema para avaliar o número de cópia de uma sequência de ácido nucleico de interesse.
EP4282977A3 (en) Spatially distinguished, multiplex nucleic acid analysis of biological specimens
CN104404145B (zh) 一种基于lamp方法快速检测肉类掺假的试剂盒
BR112015023394B8 (pt) Sistema e complexo bioluminescente
MX340330B (es) Metodo y producto para le deteccion localizada o espacial de acido nucleico en una muestra de tejido.
BR112014009269A8 (pt) diagnóstico de aneuploidia cromossômica fetal
BR112022026254A2 (pt) Sistemas e métodos para análise de uma amostra biológica
BR112019005810A2 (pt) método para sequenciamento de microbioma melhorado para caracterizar uma afecção relacionada a micro-organismo para um usuário associado a uma amostra biológica, e método para sequenciamento de microbioma melhorado
BR112019006879A2 (pt) sistema de análise e método para testagem de uma amostra
WO2015130696A8 (en) Reduction of bias in genomic coverage measurements
EP4418274A3 (en) Applications of plasma mitochondrial dna analysis
CL2022000126A1 (es) Polinucleótidos para la amplificación y detección de neisseria gonorrhoeae
BR112014014307A2 (pt) métodos e kits para detecção in situ à temperatura ambiente de um ácido nucleico alvo em uma amostra biológica
EA201590455A1 (ru) Способ анализа нуклеиновой кислоты-мишени, набор и анализатор
BR112014012773A2 (pt) ensaio de polimorfismo de nucleotídeo único de alto rendimento
CA3077390A1 (en) Methods and compositions for nucleic acid detection
Faux et al. High-throughput real-time PCR and melt curve analysis for sexing Southern Ocean seabirds using fecal samples
MX2016002210A (es) Analisis digital de analitos moleculares usando metodos electricos.
EP3342876A3 (en) Methods for detecting gastrointestinal pathogen nucleic acid
MX2018006146A (es) Modificación de diana para seguimiento y detección.
EA201792628A2 (ru) Способ специфической идентификации последовательностей днк